Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis

Abstract

Introduction

HbA1c is the most accepted laboratory parameter for the long term observation of glucose control. There is still much of a debate about the use of HbA1c as a metabolic indicator in diabetic patients (DM) on haemodialysis (HD) and erythropoiesis-stimulating agent (ESA) therapy because of the altered erythrocyte turn over in patients with chronic kidney disease and haemodialysis (CKD5D).

Patients and Methods

In 102 CKD5 patients with and without diabetes mellitus, we examined the dose dependent variability in HbA1c and fructosamine levels under haemodialysis and treated with epoetin α (n=48) and a new generation agent with continuous stimulation of methoxy polyethylene glycol epoetin beta (C.E.R.A.; n=54).

Results

HbA1c levels were affected by therapy with ESA treatments. ESA dose was inversely correlated with HbA1c and an escalation of 10.000 IU per week induced an estimated decrease of HbA1c of 0.6 percent. In addition, the increase of reticulocyte number as a marker for erythropoiesis was significantly inversely correlated with the increase of ΔHbA1c. ESA treatments had no such effect on the alternative metabolic parameter fructosamine. When compared, both therapeutic agents had comparable success in attaining haemoglobin (Hb) target values. C.E.R.A. showed better correlation and was more effective over a longer dose interval.

Conclusions

Our results show that HbA1c levels in patients should be carefully interpreted based on interfering factors. Nevertheless, HbA1c is currently the most consistent parameter for use ascertaining metabolic status of patients suffering from diabetes mellitus.

Key words

HbA1c - fructosamine - haemodialysis - erythropoiesis-stimulating agents - C.E.R.A. - epoietin α

^* Both authors contributed equally

• References

• 1 Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diab5etes Care 2016; 39 (Suppl. 01) S4-S5
• 2 Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Diabetes Care 2016; 39 (Suppl. 01) S107-S108
• 3 Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin Diabetes 2016; 34: 3-21
• 4 Holman RR, Paul SK, Bethel MA. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
• 5 Knapik P, Ciesla D, Filipiak K. et al. Prevalence and clinical significance of elevated preoperative glycosylated hemoglobin in diabetic patients scheduled for coronary artery surgery. Eur J Cardiothorac Surg 2011; 39: 484-489
• 6 van Leiden HA, Dekker JM, Moll AC. et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol 2003; 121: 245-251
• 7 Ishimura E, Okuno S, Kono K. et al. Glycemic control and survival of diabetic hemodialysis patients – importance of lower hemoglobin A1C levels. Diabetes Res Clin Pract 2009; 83: 320-326
• 8 Morioka T, Emoto M, Tabata T. et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 909-913
• 9 Oomichi T, Emoto M, Tabata T. et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500
• 10 Shepard JG, Airee A, Dake AW. et al Limitations of A1c Interpretation. South Med J 2015; 108: 724-729
• 11 Williams ME, Lacson Jr. E, Wang W. et al Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 2010; 5: 1595-1601
• 12 Bejan-Angoulvant T, Cornu C, Archambault P. et al. Gueyffier Fand Boussageon R. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. Diabetes Metab 2015; 41: 195-201
• 13 Boussageon R, Gueyffier F, Cornu C. Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?. Diabetes Metab 2014; 40: 169-175
• 14 Boussageon R. Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes. Lancet 2014; 384: 1096-1097
• 15 Williams ME, Mittman N, Ma L. et al. The glycemic indices in dialysis evaluation (gide) study: comparative measures of glycemic control in diabetic dialysis patients. Hemodial Int 2015; 19: 562-571
• 16 Tascona DJ, Morton AR, Toffelmire EB. et al Adequacy of glycemic control in hemodialysis patients with diabetes. Diabetes Care 2006; 29: 2247-2251
• 17 Tsujimoto Y, Ishimura E, Tahara H. et al. Poor glycemic control is a significant predictor of cardiovascular events in chronic hemodialysis patients with diabetes. Ther Apher Dial 2009; 13: 358-365
• 18 Obi Y, Rhee CM, Mathew AT et al. Residual kidney function decline and mortality in incident hemodialysis patients. J Am Soc Nephrol 2016
• 19 Obi Y, Streja E, Rhee CM. et al. Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: A cohort study. Am J Kidney Dis 2016; 68: 256-265
• 20 Mathew AT, Fishbane S, Obi Y. et al Preservation of residual kidney function in hemodialysis patients: reviving an old concept. Kidney Int 2016; 90: 262-271
• 21 Kim KJ, Lee BW. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab J 2012; 36: 98-107
• 22 Zheng CM, Ma WY, Wu CC. et al Glycated albumin in diabetic patients with chronic kidney disease. Clin Chim Acta 2012; 413: 1555-1561
• 23 Nakao T, Matsumoto H, Okada T. et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37: 826-830
• 24 Shafi T, Sozio SM, Plantinga LC. et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. Diabetes Care 2013; 36: 1522-1533
• 25 Dominiczak MH, Orrell JM, Finlay WE. The effect of hypoalbuminaemia, hyperbilirubinaemia and renal failure on serum fructosamine concentration in non-diabetic individuals. Clin Chim Acta 1989; 182: 123-129
• 26 Beardsworth SF, Vernon V, Harrison D. Fructosamines in uraemia and renal replacement therapy. Nephrol Dial Transplant 1989; 4: 748-749
• 27 Mittman N, Desiraju B, Fazil I. et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl 2010; S41-S45
• 28 Malmstrom H, Walldius G, Grill V. et al Fructosamine is a risk factor for myocardial infarction and all-cause mortality - Longitudinal experience from the AMORIS cohort. Nutr Metab Cardiovasc Dis 2015; 25: 943-950
• 29 Selvin E, Rawlings AM, Lutsey PL. et al. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation 2015; 132: 269-277
• 30 Group KAW. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; Suppl 2: 279-335
• 31 NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National kidney foundation-dialysis outcomes quality initiative. Am J Kidney Dis 1997; 30: S192-S240
• 32 KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
• 33 Agarwal R. Individualizing decision-making – resurrecting the doctor-patient relationship in the anemia debate. Clin J Am Soc Nephrol 2010; 5: 1340-1346
• 34 Ofsthun N, Labrecque J, Lacson E. et al The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63: 1908-1914
• 35 Williams ME, Lacson Jr. E, Teng M. et al Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503-1509
• 36 Williams SA, Buysman EK, Hulbert EM. et al. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care 2012; 21: 40-48
• 37 Sany D, Elshahawy Y, Anwar W. Glycated albumin versus glycated hemoglobin as glycemic indicator in hemodialysis patients with diabetes mellitus: variables that influence. Saudi J Kidney Dis Transpl 2013; 24: 260-273
• 38 Inaba M, Okuno S, Kumeda Y. et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903
• 39 Besarab A, Bolton WK, Browne JK. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
• 40 Singh AK, Szczech L, Tang KL. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
• 41 Eckardt KU, Kim J, Kronenberg F. et al. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol 2010; 21: 1765-1775
• 42 Uzu T, Hatta T, Deji N. et al. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A(1c). Ther Apher Dial 2009; 13: 89-94
• 43 Brown JN, Kemp DW, Brice KR. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009; 29: 468-472
• 44 Israel E, Geara A, Maarouf O. et al. Correlation between glycated hemoglobin and mean plasma glucose in hemodialysis patients. Int Urol Nephrol 2011; 43: 1149-1153
• 45 Mann JF, de Francisco A, Nassar G. et al. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol 2011; 76: 9-15